ProLung Announces Fully Subscribed Private Placement of $3.3 Million In News Salt Lake City, UT, May 22, 2020 – ProLung, Inc. (“ProLung” or the “Company”), which has... Read More
ProLung, Inc. Called One of the “50 Most Innovative Companies to Watch in 2020” by CEO Views In Awards and Recognition ProLung, Inc. is proud to announce it is one of the “50 Most Innovative Companies... Read More
ProLung Test is honored as “Most Innovative Non-Invasive Lung Cancer Testing Solution 2020” by Global Health & Pharma In Awards and Recognition, News ProLung has been awarded the “Most Innovative Non-Invasive Lung Cancer Testing Solution 2020” by Global... Read More
In Their Words: Jared Bauer In Awards and Recognition, News In Their Words: Jared Bauer Utah has an incredibly strong life sciences community with a rich... Read More
ProLung Test Granted ‘Breakthrough Device’ Designation by the FDA In Awards and Recognition, News ProLung Test Granted ‘Breakthrough Device’ Designation by the FDA Salt Lake City, UT, February 13, 2020... Read More
ProLung Announces End of 2012-2014 Governance Issues In News ProLung Announces End of 2012-2014 Governance Issues Salt Lake City, UT, February 13, 2020 – ProLung,... Read More
CEO Today Magazine Honors ProLung CEO Jared Bauer for Leadership and Strategic Vision in 2019 In Awards and Recognition, News We are delighted to share that Jared Bauer, ProLung CEO, has been honored for his... Read More
ProLung Announces Change to its Board of Directors In News ProLung Announces Change to its Board of Directors Salt Lake City, UT, November 26, 2019 –... Read More
ProLung, Inc. presents highest combined sensitivity and specificity values for a truly non-invasive lung cancer solution pursuing FDA clearance at ISRD & ATS joint medical conference In News ProLung, Inc. presents highest combined sensitivity and specificity values for a truly non-invasive lung cancer... Read More
ProLung, Inc. Announces Large Clinical Validation Trial Results of 84% sensitivity and 74% specificity In News ProLung, Inc. Announces Large Clinical Validation Trial Results of 84% sensitivity and 73% specificity Salt Lake... Read More
ProLung Promotes Jared Bauer from interim CEO to CEO In News ProLung Promotes Jared Bauer from interim CEO to CEO Salt Lake City, UT, October 2, 2019... Read More
ProLung Announces the Appointment of Leavitt Partners and Mr. Rich McKeown to its Board of Directors In News ProLung Announces the Appointment of Leavitt Partners and Mr. Rich McKeown to its Board of... Read More